QNRX

Quoin Pharmaceuticals Lt-adr

-$4.3M

Net Activity

Institutions Holding

21

Popularity Rank

#8096

Avg Weight

0.08%

Total Value

$7.8M

Ownership Trend

21 institutions currently hold QNRX, with 13 net buyers and 7 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

7

Net Buying Institutions

13

Key Holders

View all 21 holding institutions

Quarterly Activity

Recent Activity

+$4.6M

Total Buy Value

$2.7M

Total Sell Value

New buy6
Trim4
Add7
Sold out3

13

Net Buyers

7

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding QUOIN PHARMACEUTICALS LT-ADR (QNRX)?
Major stakeholders currently include Ikarian Capital, LLC ($1.4M), Dauntless Investment Group, LLC ($1.3M), SummitTX Capital, L.P. ($662.0K). Based on the latest 13F filings, there are a total of 21 tracked investment funds and institutions maintaining positions in QNRX.
What is the overall institutional sentiment toward QNRX recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $4.3M, driven by 13 managers accumulating shares while 7 reduced their exposure.
Which institutions have been selling or reducing their QNRX positions?
In the latest period, 4 funds trimmed their holdings, and 3 managers completely exited their positions. The aggregate reported sell value was $2.7M.
Are there any notable investors adding QNRX to their portfolios?
Yes, buying activity remains notable. 6 institutions opened new positions in {ticker}, and 7 existing holders added to their shares. The total reported buy value for the quarter amounted to $4.6M.

Related Stocks